Roche: successful phase ii/iii study in Covid-19
(CercleFinance.com) - Today Roche confirms positive data from the phase II/III 2066 study, involving Ronapreve (casirivimab and imdevimab) in hospitalised patients suffering from Covid-19, with the trial having met its primary endpoint.
Ronapreve significantly reduced viral load within seven days of treatment in patients who did not develop a natural immune response and who did not require high-flow oxygen or mechanical ventilation to begin with.
The full results of the study will be presented this Thursday, at ID Week 2021. The clinical data complements previous results in hospitals, including those of the RECOVERY trial conducted by the University of Oxford in the UK.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Ronapreve significantly reduced viral load within seven days of treatment in patients who did not develop a natural immune response and who did not require high-flow oxygen or mechanical ventilation to begin with.
The full results of the study will be presented this Thursday, at ID Week 2021. The clinical data complements previous results in hospitals, including those of the RECOVERY trial conducted by the University of Oxford in the UK.
Copyright (c) 2021 CercleFinance.com. All rights reserved.